PT Phapros Tbk

IDX:PEHA Stock Report

Market Cap: Rp275.5b

Phapros Past Earnings Performance

Past criteria checks 0/6

Phapros's earnings have been declining at an average annual rate of -63.1%, while the Pharmaceuticals industry saw earnings growing at 15.7% annually. Revenues have been declining at an average rate of 2.3% per year.

Key information

-63.1%

Earnings growth rate

-63.1%

EPS growth rate

Pharmaceuticals Industry Growth20.4%
Revenue growth rate-2.3%
Return on equity-6.7%
Net Margin-5.8%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Phapros makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

IDX:PEHA Revenue, expenses and earnings (IDR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24806,399-46,654351,3950
30 Jun 24827,032-51,246366,4130
31 Mar 24924,200-28,189379,4620
31 Dec 231,014,1305,959402,3990
30 Sep 231,071,955-4,208430,2980
30 Jun 231,157,88224,676434,0580
31 Mar 231,160,18927,179433,2320
31 Dec 221,168,47428,070426,8310
30 Sep 221,160,70017,310416,3750
30 Jun 221,150,71311,787420,5600
31 Mar 221,095,4139,516413,1510
31 Dec 211,051,44411,071387,6970
30 Sep 211,047,4609,361398,6660
30 Jun 21992,87032,033397,0200
31 Mar 21976,47969,478404,1910
31 Dec 20980,55748,488393,5710
30 Sep 201,013,75892,050401,1880
30 Jun 201,007,23581,161388,4600
31 Mar 201,156,94383,113432,1020
31 Dec 191,105,420102,034422,5200
30 Sep 191,117,74396,573413,7330
30 Jun 191,167,715127,344420,1620
31 Mar 191,060,784124,930382,7560
31 Dec 181,022,970132,307369,5280
30 Sep 181,058,665148,930369,7800
31 Dec 171,002,126125,266364,3140
31 Dec 16816,13387,002312,8790

Quality Earnings: PEHA is currently unprofitable.

Growing Profit Margin: PEHA is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: PEHA is unprofitable, and losses have increased over the past 5 years at a rate of 63.1% per year.

Accelerating Growth: Unable to compare PEHA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PEHA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (4%).

Return on Equity

High ROE: PEHA has a negative Return on Equity (-6.69%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 03:16
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

PT Phapros Tbk is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Natalia SutantoPT BRI Danareksa Sekuritas, Research Division